Gland Pharma Limited — Others, 20-05-2025: Appointment

Gland Pharma has announced a board meeting to approve the financial results for the quarter and half-year. Consolidated revenue stood at ₹5,616.5 Cr, down 1% year-on-year, with an improved gross margin of 62%. EBITDA declined 5% to ₹1,268.9 Cr (24% margin), and profit after tax fell 10% to ₹698.5 Cr. The core business saw a 1% revenue dip but a 200 bps rise in EBITDA margin to 35% and PAT margin at 26%. The company launched four new molecules, filed 24 ANDAs in the US during the year, and now has 318 approved ANDAs out of 371 filings. The acquired Cenexi business grew revenue by 0.3% and targets positive EBITDA by Q3 FY26. Gland Pharma secured USFDA clearances for Hyderabad facilities and is investing in complex injectables, biologics CDMO, and novel delivery systems. The board has proposed a final dividend of ₹18 per share, subject to approval.